Absci (ABSI) versus Its Competitors Head to Head Survey

Absci (NASDAQ:ABSI) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Absci to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.

Risk & Volatility

Absci has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Absci’s peers have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.

Institutional and Insider Ownership

52.0% of Absci shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 10.5% of Absci shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Absci and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	0	11	0	2.83
Absci Competitors	9761	15023	45236	1570	2.54

Absci currently has a consensus target price of $14.50, indicating a potential upside of 30.28%. As a group, “Biotechnology” companies have a potential upside of 95.52%. Given Absci’s peers higher possible upside, analysts clearly believe Absci has less favorable growth aspects than its peers.

Profitability

This table compares Absci and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Absci Competitors	-9,054.31%	-198.21%	-30.53%

Earnings and Valuation

This table compares Absci and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Absci	$2.80 million	-$115.18 million	-13.91
Absci Competitors	$716.26 million	$12.25 million	-10.31

Absci’s peers have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Absci peers beat Absci on 7 of the 13 factors compared.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.